Merck CEO Rob Davis anticipates faster production timeline for breakthrough cancer vaccine developed with Moderna
Merck's CEO Rob Davis anticipates that the manufacturing timeline for its personalized cancer vaccine, developed in partnership with Moderna, will shorten over time, potentially increasing patient access. This development is crucial as it aligns with Merck's strategy to maintain revenue streams amid the impending loss of exclusivity for its leading drug, Keytruda.